DK3454871T3 - Manipulerede naturlige dræberceller og anvendelser deraf - Google Patents

Manipulerede naturlige dræberceller og anvendelser deraf Download PDF

Info

Publication number
DK3454871T3
DK3454871T3 DK17825774.7T DK17825774T DK3454871T3 DK 3454871 T3 DK3454871 T3 DK 3454871T3 DK 17825774 T DK17825774 T DK 17825774T DK 3454871 T3 DK3454871 T3 DK 3454871T3
Authority
DK
Denmark
Prior art keywords
applications
natural killer
killer cells
manipulated
manipulated natural
Prior art date
Application number
DK17825774.7T
Other languages
Danish (da)
English (en)
Inventor
Michael Eamon Peter O'dwyer
Original Assignee
Onkimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60937693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3454871(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onkimmune Ltd filed Critical Onkimmune Ltd
Application granted granted Critical
Publication of DK3454871T3 publication Critical patent/DK3454871T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001126—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17825774.7T 2016-12-09 2017-12-11 Manipulerede naturlige dræberceller og anvendelser deraf DK3454871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662432302P 2016-12-09 2016-12-09
PCT/EP2017/082292 WO2018104562A1 (en) 2016-12-09 2017-12-11 Engineered natural killer cells and uses thereof

Publications (1)

Publication Number Publication Date
DK3454871T3 true DK3454871T3 (da) 2019-09-16

Family

ID=60937693

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19176141.0T DK3581190T3 (da) 2016-12-09 2017-12-11 Manipulerede naturlige dræberceller og anvendelser deraf
DK17825774.7T DK3454871T3 (da) 2016-12-09 2017-12-11 Manipulerede naturlige dræberceller og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19176141.0T DK3581190T3 (da) 2016-12-09 2017-12-11 Manipulerede naturlige dræberceller og anvendelser deraf

Country Status (12)

Country Link
US (2) US10799536B2 (OSRAM)
EP (4) EP3895712B1 (OSRAM)
JP (2) JP7228900B2 (OSRAM)
KR (1) KR20190114966A (OSRAM)
CN (2) CN110248669B (OSRAM)
AU (1) AU2017371517B2 (OSRAM)
BR (1) BR112019011450A2 (OSRAM)
CA (1) CA3045386A1 (OSRAM)
DK (2) DK3581190T3 (OSRAM)
ES (3) ES2746856T3 (OSRAM)
MX (1) MX2019006598A (OSRAM)
WO (1) WO2018104562A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB2567093A (en) * 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
DK3581190T3 (da) * 2016-12-09 2021-06-07 Onk Therapeutics Ltd Manipulerede naturlige dræberceller og anvendelser deraf
US20210228630A1 (en) * 2018-05-16 2021-07-29 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
JP7241161B2 (ja) * 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
TWI785268B (zh) * 2018-08-29 2022-12-01 中央研究院 用於治療癌症的自然殺手細胞與環磷醯胺的組合
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
EP3958875A4 (en) * 2019-04-25 2023-05-10 Purdue Research Foundation MANIPULATED NATURAL KILLER CELLS TARGETING PURINGERIC SIGNALING, THEIR CONSTRUCTS AND METHODS OF USE
AU2020375053A1 (en) * 2019-10-31 2022-05-26 Research Institute At Nationwide Children's Hospital Generation of CD38 knock-out primary and expanded human NK cells
US20230036481A1 (en) * 2020-01-16 2023-02-02 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021209625A1 (en) * 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells
KR20220027785A (ko) * 2020-08-27 2022-03-08 주식회사 셀리드 신규한 코로나바이러스 재조합 스파이크 단백질, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 포함하는 코로나바이러스감염증 예방 또는 치료용 백신
US20240141295A1 (en) 2020-08-31 2024-05-02 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
CN114426583B (zh) * 2020-10-29 2023-10-10 中国科学技术大学 用于急性髓系白血病的细胞疗法的嵌合抗原受体
KR20220091426A (ko) 2020-12-23 2022-06-30 주식회사 휴먼셀바이오 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물
JP2024522756A (ja) 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
WO2023278811A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
US20240327521A1 (en) * 2021-07-29 2024-10-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Synthetic nucleic acid elements for enhancing car t cell efficacy
CA3231204A1 (en) * 2021-09-18 2023-03-23 Feng Wang-Johanning Herv-k antibody, cell, vaccine, and drug therapeutics
KR20250005564A (ko) * 2021-12-03 2025-01-09 유타대학연구재단 고선택성 cd229 항원 결합 도메인 및 사용 방법
KR20250060188A (ko) 2022-06-30 2025-05-07 인답타 세라뷰틱스 인코포레이티드 조작된 자연 살해(nk) 세포 및 항체 요법의 조합 및 관련 방법
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024100203A1 (en) 2022-11-10 2024-05-16 Onk Therapeutics Limited Combined therapies using immunomodulating drugs
WO2024238387A1 (en) * 2023-05-12 2024-11-21 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025073908A1 (en) 2023-10-05 2025-04-10 Onk Therapeutics Limited Optimised il-15 constructs
WO2025146467A1 (en) 2024-01-04 2025-07-10 Onk Therapeutics Limited Targeted il-15 construct delivery
KR20250118299A (ko) 2024-01-29 2025-08-06 인하대학교 산학협력단 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213432A1 (en) * 2003-02-14 2004-09-02 Sagres Discovery, Inc. Novel therapeutic targets in cancer
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
AU2007311002B2 (en) 2006-10-19 2012-01-12 Csl Limited Antibody antagonists of interleukin-13 receptor alpha 1
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
WO2014138704A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
CA2937750A1 (en) * 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
CA2937711C (en) * 2014-02-14 2020-10-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
PL3237436T3 (pl) 2014-12-24 2020-03-31 Aadigen, Llc Peptydy i nanocząsteczki do wewnątrzkomórkowego dostarczania cząsteczek
WO2016109668A1 (en) 2014-12-31 2016-07-07 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2989347A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
TW202444897A (zh) 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
ES2939084T3 (es) 2015-07-29 2023-04-18 Onk Therapeutics Ltd Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
DK3581190T3 (da) 2016-12-09 2021-06-07 Onk Therapeutics Ltd Manipulerede naturlige dræberceller og anvendelser deraf

Also Published As

Publication number Publication date
WO2018104562A1 (en) 2018-06-14
AU2017371517A1 (en) 2019-07-04
JP7228900B2 (ja) 2023-02-27
EP3454871A1 (en) 2019-03-20
EP3581190A1 (en) 2019-12-18
CN110248669A (zh) 2019-09-17
EP3581190B1 (en) 2021-03-10
US20180161371A1 (en) 2018-06-14
ES2875005T3 (es) 2021-11-08
RU2019121509A (ru) 2021-01-11
DK3581190T3 (da) 2021-06-07
EP3895712B1 (en) 2022-06-22
BR112019011450A2 (pt) 2019-10-15
RU2019121509A3 (OSRAM) 2021-03-30
JP2020503891A (ja) 2020-02-06
EP4104841A1 (en) 2022-12-21
US20210046118A1 (en) 2021-02-18
JP2023052980A (ja) 2023-04-12
ES2746856T3 (es) 2020-03-09
CN117305250A (zh) 2023-12-29
MX2019006598A (es) 2019-10-15
KR20190114966A (ko) 2019-10-10
AU2017371517B2 (en) 2023-01-05
EP3895712A1 (en) 2021-10-20
CA3045386A1 (en) 2018-06-14
CN110248669B (zh) 2023-09-08
ES2926397T3 (es) 2022-10-26
US10799536B2 (en) 2020-10-13
EP3454871B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
DK3454871T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
EP3562492A4 (en) GENETICALLY MODIFIED NATURAL KILLER CELLS
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3988117T3 (da) Terapeutiske antistoffer og deres anvendelser
DK3668512T3 (da) Pyruvatkinasemodulatorer og anvendelse deraf
DK3189081T3 (da) Cd123-bindende midler og anvendelser deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3317401T3 (da) Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK3099172T3 (da) Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
DK3268470T3 (da) Transposasepolypeptider og anvendelser deraf
DK3559227T3 (da) Proteasevarianter og anvendelser deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3100050T3 (da) Immobiliserede proteiner og anvendelse deraf
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf